M. Hedgcock

People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses

J. Montaner, M. DeMarco, G. Umviligihozo, 2022, The Journal of infectious diseases.

People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses

G. Umviligihozo, P. Sereda, S. Datwani, 2022, medRxiv.

Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy

J. Montaner, M. DeMarco, G. Umviligihozo, 2022, npj Vaccines.

Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy

J. Montaner, M. DeMarco, G. Umviligihozo, 2021, medRxiv : the preprint server for health sciences.

38. Anal cancer screening in HIV primary care: uptake and outcomes

C. Kovacs, J. Raboud, L. Calzavara, 2013 .

Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy

J. Montaner, M. DeMarco, G. Umviligihozo, 2022, AIDS.